Drug Trial Radar · NCT06891443
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Jun 4, 2025
Primary completion
Nov 2027
Study completion Oct 2028
Sponsor
- Lead sponsor
- Laboratoires TheaIndustry
- Sponsor type
- Industry
- Collaborators
- Sepul Bio
- First posted
- Mar 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this double-masked, randomized, placebo-controlled, paired-eye study is to evaluate the efficacy, safety and tolerability of Sepofarsen in subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A\>G (p.Cys998X) mutation in the CEP290.
Conditions
- Leber Congenital Amaurosis 10
- Blindness
- Leber Congenital Amaurosis
- Sensation Disorders
- Vision Disorder
- Neurological Manifestations
- Eye Diseases, Hereditary
- Eye Diseases
- Eye Disorders Congenital
- Retinal Disease
Interventions
sepofarsenDrug
RNA antisense oligonucleotide for intravitreal injection
Placebo IVTOther
Placebo with identical appearance to sepofarsen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Best-Corrected Visual Acuity (BCVA)Time frame: 12 Months
Locations
18 sites in 10 countries. Site status is shown where the registry gives one.
UCSF Wayne and Gladys Valley Center for Vision
San Francisco, California · Recruiting
University of Miami - Bascom Palmer Eye Institute
Miami, Florida · Recruiting
University of Iowa
Iowa City, Iowa · Recruiting
University of Minnesota Medical School
Minneapolis, Minnesota · Withdrawn
University of Pennsylvania - Center for Advanced Retinal & Ocular Therapeutics
Philadelphia, Pennsylvania · Recruiting
Sydney Eye Hospital
Sydney, New South Wales, Australia · Recruiting
Universitair Ziekenhuis Gent (UZ)
Ghent, Belgium · Recruiting
INRET Clínica/ Santa Casa de Misericórdia de Belo Horizonte
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Federal University of São Paulo - Hospital São Paulo (UNIFESP-HSP)
São Paulo, São Paulo, Brazil · Recruiting
University of Alberta
Edmonton, Alberta, Canada · Recruiting
The Hospital for Sick Children - SickKids
Toronto, Ontario, Canada · Recruiting
Centre de maladies rares CHNO des Quinze Vingt
Paris, France · Recruiting
Justus-Liebig Universität - Department of Ophthalmology
Giessen, Germany · Recruiting
Klinikum der Ludwig-Maximilian Universität München
München, Germany · Recruiting
University of Tuebingen - Inst. for Ophthalmic Research
Tübingen, Germany · Recruiting
Radboud Universitair Medisch Centrum
Nijmegen, Netherlands · Recruiting
Hospital Sant Joan de Déu (SJD Barcelona Children's Hospital)
Barcelona, Spain · Recruiting
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.